BioCentury
ARTICLE | Clinical News

RP5063: Phase II data

April 29, 2013 7:00 AM UTC

Top-line data from the double-blind, international Phase II REFRESH trial in 234 patients showed that RP5063 was well tolerated with no clinically important differences in systemic side effects report...